Compare Novavax Inc (NVAX) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Snap On Incorporated — how do they compare? Novavax Inc trades at $12.97 (market cap $1.82B), while Snap On Incorporated trades at $362.54 (market cap $18.56B). The key difference: Snap On Incorporated is far larger — about 10.2× Novavax Inc's market cap, and Snap On Incorporated pays a 2.72% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Snap On Incorporated for 37 Days on average.
| NVAX | SNA | |
|---|---|---|
Market Cap | $1.82B | $18.56B |
Volume | 6,198,505 | 401,326 |
Sector | Health | Industrials |
52-Week High | $12.56 | $419.31 |
52-Week Low | $6.22 | $327.33 |
Typical Hold Time | 59 Days | 37 Days |
Enterprise Value | $1.39B | $18.20B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Snap-On Incorporated (SNA) trades at $359.89, down 2.37% on the day, with technical indicators showing bearish momentum despite strong fundamentals. The company maintains robust profitability with 19.6% net margins and 17.58% ROE, supported by consistent earnings beats in recent quarters. Analyst consensus remains bullish with a $449 price target, representing 25% upside potential from current levels.
SNA offers attractive fundamentals with expanding gross margins and solid cash flow generation, though technical weakness and premium valuation present near-term headwinds. The stock's investment case hinges on continued execution of RCI initiatives and diagnostic segment growth, balanced against valuation concerns and mixed technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
